EUVIMEDEUVIMED entdecken
Open Access

Anti–SARS-CoV-2 Pharmacotherapies Among Nonhospitalized US Veterans, January 2022 to January 2023

Lei Yan, Elani Streja, Yuli Li, Nallakkandi Rajeevan, Mazhgan Rowneki, Kristin Berry, Denise M Hynes, Francesca Cunningham, Grant D Huang, Mihaela Aslan, George N Ioannou, Kristina L Bajema

JAMA Network Open · 2023

DOI: 10.1001/jamanetworkopen.2023.31249 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, 2023. Verfasst von Lei Yan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Veterans Affairs Cooperative Studies Program Clinical Epidemiology Research Center, Veterans Affairs Connecticut Healthcare System, West Haven, Conne…. Hauptthemen laut MEDLINE: COVID-19, Veterans. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: HSRD VA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Several pharmacotherapies have been authorized to treat nonhospitalized persons with symptomatic COVID-19. Longitudinal information on the use of these therapies is needed.

Objective

To analyze trends and factors associated with prescription of outpatient COVID-19 pharmacotherapies within the Veterans Health Administration (VHA). Design, Setting, and Participants This cohort study evaluated nonhospitalized veterans in VHA care who tested positive for SARS-CoV-2 from January 2022 through January 2023 using VHA and linked Community Care and Medicare databases. Exposures Demographic characteristics, underlying medical conditions, COVID-19 vaccination, and regional and local systems of care, including Veterans Integrated Services Networks (VISNs). Main Outcomes and Measures Monthly receipt of any COVID-19 pharmacotherapy (nirmatrelvir-ritonavir, molnupiravir, sotrovimab, or bebtelovimab) was described. Multivariable logistic regression was used to identify factors independently associated with receipt of any vs no COVID-19 pharmacotherapy.

Results

Among 285 710 veterans (median [IQR] age, 63.1 [49.9-73.7] years; 247 358 males [86.6%]; 28 444 Hispanic [10.0%]; 61 269 Black [21.4%] and 198 863 White [69.6%]) who tested positive for SARS-CoV-2 between January 2022 and January 2023, the proportion receiving any pharmacotherapy increased from 3285 of 102 343 veterans (3.2%) in January 2022 to 5180 of 21 688 veterans (23.9%) in August 2022. The proportion declined to 2194 of 10 551 veterans (20.8%) by January 2023. Across VISNs, the range in proportion of patients who tested positive who received nirmatrelvir-ritonavir or molnupiravir during January 2023 was 41 of 692 veterans (5.9%) to 106 of 494 veterans (21.4%) and 2.1% to 120 of 1074 veterans (11.1%), respectively. Veterans receiving any treatment were more likely to be older (adjusted odds ratio [aOR] for ages 65-74 vs 50-64 years, 1.18; 95% CI, 1.14-1.22; aOR for ages ≥75 vs 50-64 years, 1.19; 95% CI, 1.15-1.23) and have a higher Charlson Comorbidity Index score (aOR for CCI ≥6 vs 0, 1.52; 95% CI, 1.44-1.59). Compared with White veterans, Black veterans (aOR, 1.06; 95% CI, 1.02-1.09) were more likely to receive treatment, and compared with non-Hispanic veterans, Hispanic veterans (aOR 1.06; 95% CI, 1.01-1.11) were more likely to receive treatment.

Conclusions

And Relevance This study found that prescription of outpatient COVID-19 pharmacotherapies in the VHA peaked in August 2022 and declined thereafter. There were large regional differences in patterns of nirmatrelvir-ritonavir and molnupiravir use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19VeteransUnited StatesMaleHumansAgedMiddle AgedSARS-CoV-2RitonavirCOVID-19 VaccinesCohort StudiesMedicareCytidineHydroxylaminesLactamsLeucineNitrilesProline

Substanzen

RitonavirCOVID-19 VaccinesmolnupiravirCytidineHydroxylaminesnirmatrelvirLactamsLeucineNitrilesProline

Autor:innen und Institutionen

  • Veterans Affairs Cooperative Studies Program Clinical Epidemiology Research Center, Veterans Affairs Connecticut Healthcare System, West Haven, Connecticut.
  • Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut.
  • Center of Innovation to Improve Veteran Involvement in Care, Veterans Affairs Portland Healthcare System, Portland, Oregon.
  • Research and Development, Veterans Affairs Puget Sound Health Care System, Seattle, Washington.
  • Health Management and Policy, School of Social and Behavioral Health Sciences, College of Public Health and Human Sciences; Health Data and Informatics Program, Center for Quantitative Life Sciences, Oregon State Univer…
  • Pharmacy Benefit Management Services, Veterans Affairs Center for Medication Safety, Hines, Illinois.

Förderung

  • HSRD VA

Zitieren

APA

Yan, L., Streja, E., Li, Y., Rajeevan, N., Rowneki, M., Berry, K., Hynes, D. M., Cunningham, F., Huang, G. D., Aslan, M., Ioannou, G. N., & Bajema, K. L. (2023). Anti–SARS-CoV-2 Pharmacotherapies Among Nonhospitalized US Veterans, January 2022 to January 2023. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2023.31249

Vancouver

Yan L, Streja E, Li Y, Rajeevan N, Rowneki M, Berry K, et al. Anti–SARS-CoV-2 Pharmacotherapies Among Nonhospitalized US Veterans, January 2022 to January 2023. JAMA Network Open. 2023. doi:10.1001/jamanetworkopen.2023.31249

BibTeX
@article{Yan2023,
  author = {Yan, Lei and Streja, Elani and Li, Yuli and Rajeevan, Nallakkandi and Rowneki, Mazhgan and Berry, Kristin and Hynes, Denise M and Cunningham, Francesca and Huang, Grant D and Aslan, Mihaela and Ioannou, George N and Bajema, Kristina L},
  title = {Anti–SARS-CoV-2 Pharmacotherapies Among Nonhospitalized US Veterans, January 2022 to January 2023},
  journal = {JAMA Network Open},
  year = {2023},
  doi = {10.1001/jamanetworkopen.2023.31249}
}
Kostenlos starten →